Oki, Eiji
Shinto, Eiji
Shimokawa, Mototsugu
Yamaguchi, Shigeki
Ishiguro, Megumi
Hasegawa, Seiji
Takii, Yasumasa
Ishida, Hideyuki
Kusumoto, Tetsuya
Morita, Masaru
Tomita, Naohiro
Shiozawa, Manabu
Tanaka, Masafumi
Ozawa, Heita
Hashiguchi, Yojiro
Ohnuma, Shinobu
Tada, Sachiyo
Matsushima, Tomoko
Hase, Kazuo
Article History
Received: 1 June 2021
Accepted: 18 November 2021
First Online: 14 December 2021
Declarations
:
: The study protocol was approved by the following institutional review boards: Kyushu University (study ID 28–69), National Defense Medical College (study ID 2477), Saitama Medical University International Medical Center (study ID 16–051), Tokyo Medical and Dental University (study ID G2016–007), Saiseikai Yokohamashi Nanbu Hospital (study ID 2017-D21), Niigata Cancer Center Hospital (study ID 796), Saitama Medical University Saitama Medical Center (study ID 1812), National Hospital Organization Kyushu Medical Center (study ID 16C058), National Hospital Organization Kyushu Cancer Center (study ID 2016–48), Hyogo College of Medicine (study ID Hi326), Kanagawa Cancer Center (study ID 2017–8), Takano Hospital (study ID 16–04), Tochigi Cancer Center (study ID A432), Teikyo University School of Medicine (study ID 16–057), Tohoku University (study ID 2016–1-222) and Sysmex Corporation (study ID 2015–71). All procedures were performed in accordance with the relevant guidelines and regulations. Because this study was a retrospective observational study carried out in Japan, informed consent was obtained using the opt-out/opt-in approach according to each participating institution’s policy (as per Japanese ethical guidelines for an observational study, consent of the family is not required for dead participants).
: Not applicable.
: E.O. has been part of a speaker’s bureau at Bayer, Chugai Pharmaceutical, Eli Lilly, Merck Serono, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, and Yakult Honsha. M.S. has a consulting/advisory role at Sysmex. S.Y. has been part of a speaker’s bureau at Chugai Pharmaceutical, Covidien, Eli Lilly, Merck Serono, Johnson & Johnson, and Taiho Pharmaceutical. M.I. has received honoraria from Merck Serono, Taiho Pharmaceutical, and Yakult Honsha, and has a consulting/advisory role at Taiho Pharmaceutical and Yakult Honsha. N.T. has received research funding from Chugai Pharmaceutical and Taiho Pharmaceutical. Y.H. has received honoraria from Bayer, Chugai Pharmaceutical, Kaken Pharmaceutical, Merck Serono, Sanofi, Taiho Pharmaceutical, and Takeda Pharmaceutical, and has received research funding from Chugai Pharmaceutical, Kaken Pharmaceutical, Merck Serono, Sanofi, Taiho Pharmaceutical, and Takeda Pharmaceutical. S.T. and T.M. are employed by Sysmex and own stock shares of Sysmex. E.S., S.H., Y.T., H.I., T.K., M. M, M.S., M.T., H.O., S.O., and K.H. declare no conflicts of interest.